Adicet Bio (NASDAQ:ACET – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a research note issued on Friday, Benzinga reports. They presently have a $5.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 228.95% from the company’s previous close.
A number of other research firms also recently issued reports on ACET. StockNews.com downgraded shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Canaccord Genuity Group decreased their target price on shares of Adicet Bio from $19.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Adicet Bio in a research report on Thursday.
Read Our Latest Research Report on Adicet Bio
Adicet Bio Stock Up 4.1 %
Adicet Bio (NASDAQ:ACET – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.03. As a group, sell-side analysts expect that Adicet Bio will post -1.35 earnings per share for the current year.
Institutional Trading of Adicet Bio
A number of institutional investors have recently bought and sold shares of ACET. Vanguard Group Inc. raised its stake in shares of Adicet Bio by 85.5% in the first quarter. Vanguard Group Inc. now owns 3,126,578 shares of the company’s stock valued at $7,347,000 after acquiring an additional 1,441,503 shares during the period. Acadian Asset Management LLC raised its position in Adicet Bio by 205.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,085,093 shares of the company’s stock worth $1,312,000 after purchasing an additional 729,750 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Adicet Bio in the first quarter worth about $37,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Adicet Bio during the first quarter valued at approximately $28,000. Finally, American International Group Inc. grew its stake in shares of Adicet Bio by 74.2% during the first quarter. American International Group Inc. now owns 26,319 shares of the company’s stock valued at $62,000 after buying an additional 11,214 shares during the last quarter. 83.89% of the stock is currently owned by institutional investors.
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Featured Articles
- Five stocks we like better than Adicet Bio
- Dividend Payout Ratio Calculator
- 3 Dividend-Yielding Stocks Too Cheap to Pass Up
- How to Use the MarketBeat Excel Dividend Calculator
- Triple Witching: The Market’s Quarterly Rollercoaster
- Investing in Construction Stocks
- 4 Stocks Set to Benefit from Recent Interest Rate Cuts
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.